Skip to main content
. 2022 May 6;140(16):1753–1763. doi: 10.1182/blood.2021014956

Figure 1.

Figure 1.

Cancer genemutations in t-MNs. (A) The frequency of cancer gene mutations detected in at least 1% of the studied cohort. Stacked bar graph shows the share of the mutations detected in t-AML and t-MDS each. (B) Mutation enrichment against 4 disease subtypes (t-AML, t-MDS, AML, and MDS). Enrichment is measured by OR for t-AML vs AML in x-axis and t-MDS vs MDS in y-axis. Statistically significant enrichment based on OR of 95% CI is highlighted by colors. CI, confidence interval.